Immuno-Oncology and Cell Therapy

Explore By Subject Area

Serving the IO and Cell Therapy Community

Lead Podcast

Debate on Solving Immuno-Oncology's Top Challenges

Debate on Solving Immuno-Oncology's Top Challenges

The 2024 IO360º debate focuses on cell therapy versus bispecific engagers, which therapy will be most successful in solid tumors, and which therapy will lead to the next step change.

Featured Podcasts

The CMO as a Translational Scientist

The History of Tumor Vaccines, and Why the Newest RNA Vaccines May Work Where Others Could Not

Combining AI and Empirical Science to Advance Cancer Immunotherapies

Getting Under the Hood of AI to Find Its Value for Immuno-Oncology

More Related Content

Pharmatalk Radio Podcasts

Immuno-Oncology Cell Therapy Data Analytics: What to Measure and How to Measure It?

Immuno-Oncology Cell Therapy Data Analytics: What to Measure and How to Measure It?

Discoveries from the Clinic that Help Inform IO Cell Therapy Moving Forward

Discoveries from the Clinic that Help Inform IO Cell Therapy Moving Forward

Unlocking ctDNA's Potential for Prognostic Stratification, Tumor Evolution Insights & Accelerated Drug Development

Unlocking ctDNA's Potential for Prognostic Stratification, Tumor Evolution Insights & Accelerated Drug Development

Delivery Challenges from the Oncology Pipeline

Delivery Challenges from the Oncology Pipeline

Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process

Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process

Key Learnings from the Clinical Development of Approved Cell Therapy Products

Key Learnings from the Clinical Development of Approved Cell Therapy Products

Addressing the Current Market and Investment Trends in Immuno-Oncology

Addressing the Current Market and Investment Trends in Immuno-Oncology

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities

Innovative CRISPR Editing to Create Off-the-Shelf Immune Cell Therapies

Innovative CRISPR Editing to Create Off-the-Shelf Immune Cell Therapies

Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach

Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach

Investment Trends for the IO 2.0 Wave

Investment Trends for the IO 2.0 Wave

Investment and Collaboration Strategies in Cell and Gene Therapy

Investment and Collaboration Strategies in Cell and Gene Therapy

Nobel Laureate Dr Gregg Semenza Presents Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors

Nobel Laureate Dr Gregg Semenza Presents Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors

Using Neoadjuvant Immune Checkpoint Blockade as a Window into Treatment Response and Primary Resistance

Using Neoadjuvant Immune Checkpoint Blockade as a Window into Treatment Response and Primary Resistance

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development

Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment

Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment

What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum

What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum

The Role of Chinese Biotechs in the BD Process for Immuno-Oncology

The Role of Chinese Biotechs in the BD Process for Immuno-Oncology

Understanding Next-Generation Immune Checkpoints and Deciphering Key Roles in the TME

Understanding Next-Generation Immune Checkpoints and Deciphering Key Roles in the TME

Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies

Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies

A Decade After Checkpoints: What Do We Know, What Do We Need to Know?

A Decade After Checkpoints: What Do We Know, What Do We Need to Know?

Achieving Diversity and Inclusion in Oncology Clinical Trials

Achieving Diversity and Inclusion in Oncology Clinical Trials

Advancements in CAR T for the Treatment of Glioblastoma

Advancements in CAR T for the Treatment of Glioblastoma

Cell & Gene Therapy's Current Landscape, Lessons Learned and Paths Forward

Cell & Gene Therapy's Current Landscape, Lessons Learned and Paths Forward

The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health

The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health

HLA Loss and the Impact on Immunotherapy

HLA Loss and the Impact on Immunotherapy

Innovations & Novel Approaches in IO Imaging & Assessing Responses

Innovations & Novel Approaches in IO Imaging & Assessing Responses

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

Finding a Life-Saving Nivolumab Trial After a Hodgkin's Lymphoma Diagnosis

Finding a Life-Saving Nivolumab Trial After a Hodgkin's Lymphoma Diagnosis

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.

First Name*

Last Name*

Email*

Areas of Interest*